Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16403839 | 1.00 | RAMP1 (0.33) | RAMP1CALCRL | |
| SCHEMBL1690385 | 1.00 | RAMP1 (0.33) | RAMP1CALCRL | |
| SCHEMBL1092657 | 0.81 | — | — | |
| SCHEMBL1092659 | 0.81 | — | — | |
| SCHEMBL3611131 | 0.79 | RAB9A (0.40) | — | |
| SCHEMBL3611126 | 0.79 | RAB9A (0.40) | — | |
| SCHEMBL1093388 | 0.79 | — | — | |
| SCHEMBL1093390 | 0.79 | — | — | |
| SCHEMBL1255043 | 0.77 | — | — | |
| SCHEMBL1255042 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3004099-A1 | TETRAHYDROPYRIDINE DERIVATIVES AS FabI INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2016-04-13 | — | — | EP | disclosed |
| WO-2014195844-A1 | TETRAHYDROPYRIDINE DERIVATIVES AS FabI INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2014-12-11 | — | — | WO | disclosed |
| US-20140107106-A1 | THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USING THE SAME | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2014-04-17 | — | — | US | disclosed |
| US-8450307-B2 | Therapeutic agents, and methods of making and using the same | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2013-05-28 | — | — | US | disclosed |
| US-20120010127-A1 | Compositions Comprising Multiple Bioactive Agents, and Methods of Using the Same | BERMAN JUDD M (CA) | 2012-01-12 | — | — | US | disclosed |
| US-20100093705-A1 | Therapeutic agents, and methods of making and using the same | DEBIOPHARM INTERNATIONAL SA (CH) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093705-A1 | Therapeutic agents, and methods of making and using the same | MCL1, DHFR, ANXA5 | RAMP1 4827/4885CALCRL 1886/4885 |
| US-20120010127-A1 | Compositions Comprising Multiple Bioactive Agents, and Methods of Using the Same | DBI, SERPINB1, CTSF | RAMP1 4540/4885CALCRL 3743/4885 |
| US-20140107106-A1 | THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USING THE SAME | MCL1, DHFR, ANXA5 | RAMP1 4827/4885CALCRL 1886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.